SP6616 as a new Kv2.1 channel inhibitor efficiently promotes β-cell survival involving both PKC/Erk1/2 and CaM/PI3K/Akt signaling pathways
2016 · Cell Death and Disease · 37 citations
https://doi.org/10.1038/cddis.2016.119
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
8
Papers
177
Citations
7
h-index
6
i10-index
Lingling Quan is an academic researcher from Zhuzhou Central Hospital. The author has contributed to research in topics: Pancreatic function and diabetes & Advanced biosensing and bioanalysis techniques & Metabolism, Diabetes, and Cancer. The author has an h-index of 7, co-authored 7 publications.
https://doi.org/10.1038/cddis.2016.119
https://doi.org/10.3760/cma.j.cn112147-20230721-00022
Click to start Chat